标题
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-08
DOI
10.3389/fphar.2022.856111
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
- (2021) Muhammad Aetesam-ur-Rahman et al. BMC Cardiovascular Disorders
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
- (2021) Dario Giugliano et al. Cardiovascular Diabetology
- Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells
- (2021) Poonam Kapadia et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
- (2021) Federico Rea et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions
- (2020) Marieke Sternkopf et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet
- (2020) Vijayakumar Sukumaran et al. Cardiovascular Diabetology
- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- (2020) Jean-Philippe Collet et al. EUROPEAN HEART JOURNAL
- Incretin drugs effect on epigenetic machinery: New potential therapeutic implications in preventing vascular diabetic complications
- (2020) Lucia Scisciola et al. FASEB JOURNAL
- Assessment and pathophysiology of microvascular disease: recent progress and clinical implications
- (2020) Stefano Masi et al. EUROPEAN HEART JOURNAL
- Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial
- (2020) Divya Birudaraju et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction
- (2019) Hannah Elena Suhrs et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
- (2019) Juhani Knuuti et al. EUROPEAN HEART JOURNAL
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- (2019) Vinay Garg et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes
- (2019) Sajad Hamal et al. CORONARY ARTERY DISEASE
- GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
- (2019) Qian-Feng Xiong et al. Cardiology Research and Practice
- Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
- (2019) Valerie D Heuvelman et al. CARDIOVASCULAR RESEARCH
- Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance
- (2019) Nasui Wang et al. DIABETES CARE
- Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis
- (2019) Richeek Pradhan et al. Lancet Diabetes & Endocrinology
- Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation
- (2018) Wojciech Garczorz et al. Cardiovascular Therapeutics
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options
- (2018) Viviany R. Taqueti et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- GLP‐1 Is a Coronary Artery Vasodilator in Humans
- (2018) Sophie J. Clarke et al. Journal of the American Heart Association
- Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
- (2017) Michelangela Barbieri et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
- (2017) Cristina Barale et al. THROMBOSIS AND HAEMOSTASIS
- Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
- (2016) Alison Cameron-Vendrig et al. DIABETES
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study
- (2015) Rebekka Faber et al. Cardiovascular Diabetology
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
- (2015) Xiaoyan Song et al. Scientific Reports
- GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans
- (2014) Sharmila C. Subaran et al. CLINICAL SCIENCE
- Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
- (2014) Maria Luisa Balestrieri et al. DIABETES
- Coronary Microvasculature
- (2013) Habib Samady et al. Circulation-Cardiovascular Interventions
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
- (2013) D. Wang et al. DIABETES
- Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
- (2013) P. Richards et al. DIABETES
- Coronary microvascular dysfunction: an update
- (2013) F. Crea et al. EUROPEAN HEART JOURNAL
- Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways
- (2013) Özlem Erdogdu et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
- (2012) Mohammad Hossein Noyan-Ashraf et al. CIRCULATION
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
- (2011) Hiromasa Goto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mechanisms of Coronary Artery Spasm
- (2011) Gaetano Antonio Lanza et al. CIRCULATION
- Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor
- (2010) Ö. Erdogdu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search